Galapagos Abstracts@ ACR 2023

Distinct treatment responses in patients with rheumatoid arthritis receiving filgotinib 200 mg over 12 months: A post hoc analysis of FINCH 1

^{Peter C. Taylor, Yoshiya Tanaka, Emily Aiello, Thomas Debray, Chris Watson, Kristina Harris, Gerd Rüdiger Burmester}

^{Session type: Poster Session B
Poster Number: 1323}

^{Session title: RA – Treatments
09:00–11:00 PST
Poster II
Date: 13 Nov 2023}

What trade-offs are acceptable to rheumatoid arthritis patients during treatment selection?

^{Rieke Alten, Juan Carlos Nieto Gonzalez, Peggy Jacques, Carlomaurizio Montecucco, Robert Moots, Helga Radner, Sebastian Heidenreich, Chiara Whichello, Nicolas Krucien, Monia Zignani, Harald Vonkeman, Katrien Van Beneden}

^{Session type: Abstract Session
Presentation Number: 1680}

^{Session title: Abstracts: RA – Treatments II: RA Treatment
16:00–17:30 PST
Safety
Date: 13 Nov 2023}

The impact of filgotinib on disease activity outcomes with concomitant pain control in the Phase 3 FINCH studies

^{Peter C. Taylor, Arthur Kavanaugh, Peter Nash, Janet Pope, Georg Pongratz, Bruno Fautrel, Rieke Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, Rene Westhovens}

^{Session type: Poster Session C
Poster Number: 2155}

^{Session title: RA – Treatments
09:00–11:00 PST
Poster III
Date: 13 Nov 2023}

Safety and efficacy of filgotinib: an update from the DARWIN 3 Phase 2 long-term extension with a maximum of 8.2 years of exposure

^{Rene Westhovens, Rieke Alten, Lorenzo Dagna, Arthur Kavanaugh, Kevin L. Winthrop, Jane Barry, Robin Besuyen, Claudio Corallo, Dick de Vries, Nicolas Martin, Chris Watson, Mark C. Genovese, Alberto Spindler, Mykola Stanislavchuk, Maria Greenwald, Paul Emery}

^{Session type: Poster Session C
Poster Number: 2162}

^{Session title: RA – Treatments
09:00–11:00 PST
Poster III
Date: 14 Nov 2023}

Efficacy of filgotinib (FIL) in patients (pts) with rheumatoid arthritis (RA): Week (W) 156 results from a long-term extension (LTE) study

^{Maya H Buch, Daniel Aletaha, Roberto Caporali, Bernard G Combe, Hendrik Schulze-Koops, Jacques-Eric Gottenberg, Yoshiya Tan¬aka, Ricardo Blanco, Tsutomu Takeuchi, Edmund V Ekoka Omoruyi, Katrien Van Beneden, Vijay Rajendran, Chris Watson, Francesco De Leonardis, Paul Emery}

^{Session type: Poster Session C
Poster Number: 2143}

^{Session title: RA – Treatments
09:00–11:00 PST
Poster III
Date: 14 Nov 2023}

Long-term clinical profile of filgotinib (FIL) in patients (pts) with rheumatoid arthritis (RA) by cardiovascular (CV) risk factors: a post hoc subgroup analysis

^{Maya H Buch, Jose A Gómez-Puerta, Gerd Rüdiger Burmester, Bernard G Combe, Vijay Rajendran, Pieter-Jan Stiers, Paul Van Hoek, Katrien Van Beneden, Jacques-Eric Gottenberg, Yoshiya Tanaka, Daniel Aletaha, René Westhovens, Roberto Caporali}

^{Session type: Poster Session A
Poster Number: 0451}

^{Session title: RA – Treatments
09:00–11:00 PST
Poster I
Date: 12 Nov 2023}

Integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis with a maximum exposure of 8.3 years

^{Kevin Winthrop, Daniel Aletaha, Roberto Caporali, Yoshiya Tanaka, Tsutomu Takeuchi, Paul Van Hoek, Pieter-Jan Stiers, Vijay Rajendran, Katrien Van Beneden, Jacques-Eric Gottenberg, Gerd R. Burmester}

^{Session type: Poster Session B
Poster Number: 1325}

^{Session title: RA – Treatments
09:00–11:00 PST
Poster II
Date: 13 Nov 2023}

Cardiovascular (CV) and malignancy events in the filgotinib (FIL) rheumatoid arthritis (RA) clinical development program up to 8.3 years

^{Xavier Mariette, Sven Borchmann, Sandrine Aspeslagh, Jaime Calvo-Alén, Richard Moriggl, Zoltan Szekanecz, Francesco De Leonardis, Nadia Verbruggen, Paul Van Hoek, Marc Schmalzing, Andreas Stallmach, Christina Charles-Schoeman, Vijay Rajendran, Christine Rudolph, Chris Watson, Yoshiya Tanaka, Ernest Choy}

^{Session type: Poster Session B
Poster Number: 1325}

^{Session title: RA – Treatments
09:00–11:00 PST
Poster II
Date: 13 Nov 2023}